CBD Life Sciences Inc. (CBDL) Announces President Trump Confirms Marijuana Rescheduling Is Under Consideration
CBD Life Sciences (OTC:CBDL) reports that President Trump's administration is actively considering rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. This potential regulatory shift could transform the $30+ billion cannabis market by eliminating IRS Section 280E restrictions and opening doors for institutional investment.
The rescheduling would enable cannabis companies to deduct ordinary business expenses, improve net margins, and facilitate access to banking services. With nearly 70% of Americans supporting legalization, CBDL is positioning itself through retail expansion, including recent approval for sales on Walmart Marketplace, to capitalize on the anticipated industry growth following regulatory reform.
CBD Life Sciences (OTC:CBDL) riferisce che l'amministrazione del Presidente Trump sta valutando seriamente di ricollocare la marijuana dalla Schedule I alla Schedule III del Controlled Substances Act. Questo cambiamento normativo potrebbe rivoluzionare il mercato della cannabis da oltre 30 miliardi di dollari eliminando le limitazioni dell'IRS Section 280E e favorendo l'ingresso degli investitori istituzionali.
La riclassificazione consentirebbe alle aziende del settore di dedurre le normali spese operative, migliorare i margini netti e agevolare l'accesso ai servizi bancari. Con il quasi 70% degli americani a favore della legalizzazione, CBDL si sta preparando espandendo la sua presenza retail, incluso il recente via libera alle vendite su Walmart Marketplace, per sfruttare la crescita prevista dopo la riforma normativa.
CBD Life Sciences (OTC:CBDL) informa que la administraci贸n del presidente Trump est谩 considerando activamente reclasificar la marihuana de la Schedule I a la Schedule III seg煤n el Controlled Substances Act. Este posible cambio regulatorio podr铆a transformar el mercado del cannabis de m谩s de 30.000 millones de d贸lares al eliminar las restricciones de la Secci贸n 280E del IRS y abrir la puerta a la inversi贸n institucional.
La reclasificaci贸n permitir铆a a las compa帽铆as cann谩bicas deducir los gastos ordinarios de negocio, mejorar los m谩rgenes netos y facilitar el acceso a servicios bancarios. Con casi el 70% de los estadounidenses apoyando la legalizaci贸n, CBDL se est谩 posicionando mediante la expansi贸n minorista, incluida la reciente aprobaci贸n para vender en Walmart Marketplace, para capitalizar el crecimiento esperado tras la reforma regulatoria.
CBD Life Sciences (OTC:CBDL)電� 韸鸽熂頂� 雽�韱惦牴 頄夓爼攵�臧� 毵堧Μ頇旊倶毳� 韱奠牅氍检氩�(Controlled Substances Act)靸� Schedule I鞐愳劀 Schedule III搿� 鞛秳毳橅晿電� 氚╈晥鞚� 鞝侁饭 瓴�韱� 欷戩澊霛缄碃 氤搓碃頄堨姷雼堧嫟. 鞚措煬頃� 攴滌牅 氤�頇旊姅 300鞏� 雼煬 鞚挫儊鞚� 雽�毵�(旃鸽倶牍勳姢) 鞁滌灔鞚� IRS 靹轨厴 280E 鞝滍暅 頃挫唽鞕� 旮瓣磤 韴瀽 鞙犾瀰 臧�電レ劚鞙茧 鞚疙暣 韥矊 氚旉縺 靾� 鞛堨姷雼堧嫟.
鞛秳毳橁皜 鞚措歆�氅� 旃鸽倶牍勳姢 旮办梾霌れ潃 韱奠儊鞝� 靷梾 牍勳毄鞚� 牍勳毄鞙茧 瓿奠牅頃� 靾� 鞛堨柎 靾滌澊鞚惦鞚� 臧滌劆霅橁碃 鞚�頄� 靹滊箘鞀� 鞚挫毄霃� 鞗愴櫆頃挫雼堧嫟. 氙戈淡鞚胳潣 瓯办潣 70%臧� 頃╇矔頇旊ゼ 歆�歆�頃橂姅 臧�鞖措嵃, CBDL鞚� Walmart Marketplace 韺愲Г 鞀轨澑 霌� 靻岆Г 頇曥灔鞚� 韱淀暣 攴滌牅 臧滍幐 頉� 鞓堨儊霅橂姅 靷办梾 靹膘灔鞐� 雽�牍勴晿瓿� 鞛堨姷雼堧嫟.
CBD Life Sciences (OTC:CBDL) indique que l'administration du pr茅sident Trump envisage activement de reclasser le cannabis de la Schedule I 脿 la Schedule III en vertu du Controlled Substances Act. Ce changement r茅glementaire potentiel pourrait transformer le march茅 du cannabis de plus de 30 milliards de dollars en supprimant les restrictions de l'IRS Section 280E et en ouvrant la porte aux investissements institutionnels.
Le reclassement permettrait aux entreprises du secteur de d茅duire leurs d茅penses professionnelles ordinaires, d'am茅liorer leurs marges nettes et de faciliter l'acc猫s aux services bancaires. Avec pr猫s de 70 % des Am茅ricains favorables 脿 la l茅galisation, CBDL se positionne en 茅largissant sa pr茅sence retail, y compris la r茅cente approbation pour des ventes sur Walmart Marketplace, afin de tirer parti de la croissance pr茅vue suite 脿 la r茅forme r茅glementaire.
CBD Life Sciences (OTC:CBDL) berichtet, dass die Regierung von Pr盲sident Trump aktiv erw盲gt, Marihuana vom Schedule I in Schedule III des Controlled Substances Act umzustufen. Dieser m枚gliche regulatorische Schritt k枚nnte den mehr als 30 Milliarden Dollar schweren Cannabismarkt ver盲ndern, indem er die Beschr盲nkungen durch IRS Section 280E aufhebt und institutionelle Investitionen erm枚glicht.
Die Umstufung w眉rde Cannabisunternehmen erlauben, gew枚hnliche Betriebsausgaben abzusetzen, die Nettomargen zu verbessern und den Zugang zu Bankdienstleistungen zu erleichtern. Da fast 70% der Amerikaner die Legalisierung unterst眉tzen, positioniert sich CBDL durch den Ausbau des Einzelhandels, einschlie脽lich der j眉ngsten Zulassung f眉r Verk盲ufe im Walmart Marketplace, um vom erwarteten Wachstum der Branche nach der Regulierung zu profitieren.
- Potential elimination of IRS Section 280E restrictions could significantly improve company margins
- Recent approval for sales on Walmart Marketplace expands retail presence
- Possible access to new institutional capital and banking services if rescheduling occurs
- Positioned to benefit from potential $30+ billion market opportunity
- Current Schedule I status still restricts business operations
- Rescheduling consideration is not guaranteed to result in actual policy change
- Company success heavily dependent on regulatory reform
"A shift to Schedule III could unlock a
SCOTTSDALE, ARIZONA / / September 3, 2025 / CBD Life Sciences Inc. (OTC:CBDL), a leader in the development and sale of high-quality CBD and wellness products, is pleased to announce that President Donald Trump has confirmed his administration is actively considering the rescheduling of marijuana under the Controlled Substances Act. This announcement, highlighted in a recent JD Supra legal analysis, signals what may be the most pivotal regulatory moment in the history of the cannabis industry.
The administration is reviewing a proposal to reclassify cannabis from Schedule I to Schedule III, which would:
Deliver billions in tax relief: The elimination of IRS Section 280E restrictions would allow cannabis companies to deduct ordinary business expenses, improving net margins by double digits and freeing up billions in reinvestment capital across the sector.
Unlock capital markets: Banks, lenders, and institutional investors-previously sidelined due to regulatory risk-would gain clearance to enter the cannabis space, fueling an unprecedented wave of financing, credit, and equity growth.
Elevate cannabis as legitimate medicine: Federal recognition of marijuana's medical value would boost physician confidence, accelerate clinical trials, and enhance credibility with healthcare providers and patients alike.
Catalyze M&A and consolidation: Regulatory clarity would supercharge mergers, acquisitions, and strategic alliances, positioning leading companies like CBDL to seize early-mover advantage.
Ignite investor sentiment: Cannabis equities have already rallied on rescheduling optimism. A formal reclassification could spark another surge, creating generational wealth opportunities for early shareholders.
Why This Matters for CBD Life Sciences Inc.
CBD Life Sciences Inc. stands at the forefront of this coming wave. With proven retail traction, recent approvals for sale on Walmart Marketplace, and a growing pipeline of CBD and wellness innovations, the company is positioned to scale rapidly once federal restrictions ease.
"This is the moment we've been preparing for," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "The rescheduling of cannabis would remove historic barriers that have limited our industry's growth. For CBDL, it means the ability to expand faster, compete more effectively, and deliver greater long-term value for our shareholders."
Investor Highlights
President Trump confirms marijuana rescheduling is under active review.
Federal reform could unleash a
$30 + billion U.S. cannabis market opportunity.IRS 280E tax relief expected to save the industry billions annually.
Expanded access to institutional capital, banking, and financing.
Growing public approval of legalization with nearly
70% of Americans in support.CBDL is already executing growth strategy with retail expansion and product innovation.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC: CBDL) is a publicly traded company dedicated to delivering innovative, high-quality CBD and wellness products. Through its wholly owned subsidiary, The CBD Vault, the company develops, markets, and distributes a wide range of CBD tinctures, topicals, edibles, and wellness solutions available through retail and online channels.
Link To Article 1 : https://www.jdsupra.com/legalnews/president-trump-confirms-marijuana-7853330/#:~:text=President%20Trump's%20renewed%20focus%20on,financial%20relief%20for%20cannabis%20businesses
Link To Article 2 :
About CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc. is an innovative health and wellness company committed to the research, development, and distribution of premium cannabidiol (CBD) products through its core brand, CBD Vault. From topicals and tinctures to wellness beverages and skincare solutions, CBDL is building a portfolio of products designed for maximum efficacy, transparency, and consumer trust.
Follow our social media for the latest updates!
X:
Instagram:
IR Contact: [email protected]
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram:
Mushroom Madness Website:
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
4802091720
SOURCE: CBD Life Sciences, Inc.
View the original on ACCESS Newswire
FAQ
What would marijuana rescheduling to Schedule III mean for CBDL stock?
How would the potential cannabis rescheduling affect CBDL's tax situation?
What is CBDL's current retail expansion strategy?
How large is the potential market opportunity for CBDL if marijuana is rescheduled?
What percentage of Americans support cannabis legalization according to CBDL's report?
